Trial Profile

Real Life Non-interventional Study on Safety and Effectiveness of Ilaris® (Canakinumab) 150 mg for Subcutaneous Injection in Hereditary Periodic Fever Syndrome (CAPS, crFMF, TRAPS and HIDS/MKD) Patients and sJIA Patients (REASSURE)

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 05 Jan 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Canakinumab (Primary)
Indications Cryopyrin-associated periodic syndromes; Familial autosomal dominant periodic fever; Familial Mediterranean fever; Hereditary autoinflammatory diseases; Juvenile rheumatoid arthritis; Mevalonate Kinase Deficiency
Focus Adverse reactions
Acronyms REASSURE
Sponsors Novartis Pharmaceuticals

30 Dec 2025 Planned number of patients changed from 16 to 25.
30 Dec 2025 Status changed from not yet recruiting to recruiting.
20 Mar 2025 Planned initiation date changed from 28 Feb 2025 to 30 Apr 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com